Table 2.
Clinical outcome of patients who developed pneumothorax
| Clinical parameter | n | Baseline mean ± SD | Three months following pneumothorax mean ± SD | P-value |
|---|---|---|---|---|
| VC (L) | 36 | 2.54±0.79 | 2.52±0.72 | 0.856 |
| VC (%) | 35 | 72±19 | 72±18 | 0.855 |
| FEV1 (L) | 36 | 0.81±0.24 | 0.83±0.29 | 0.286 |
| FEV1 (%) | 36 | 30±9 | 31±10 | 0.270 |
| RV (L) | 34 | 5.97±1.33 | 5.65±1.50 | 0.060 |
| RV (%) | 35 | 275±60 | 257±60 | 0.029 |
| TLC (L) | 34 | 8.57±1.60 | 8.25±1.76 | 0.040 |
| TLC (%) | 35 | 144±22 | 138±17 | 0.024 |
| 6-MWT (m) | 31 | 320±90 | 330±87 | 0.548 |
| mMRC (pts) | 26 | 2.25±1.09 | 1.81±1.16 | 0.442 |
Note: Data were assessed 3 months following recovery from pneumothorax.
Abbreviations: 6-MWT, 6-minute walk test; FEV1, forced expiratory volume in 1 second; RV, residual volume; SD, standard deviation; TLC, total lung capacity; VC, vital capacity; mMRC, modified Medical Research Council.